While hospital infection by antibiotic-resistant bacterium has been a big issue, Toyama Chemical has a wealth of unsurpassed experience in development of various antibiotics and synthetic antibacterial agents with great antibacterial activity. The development of PENTCILLIN, now the synonym of a synthetic penicillin agent, and licensing to major global pharmaceutical companies are two examples of this. Infectious disease is a major field of strength for Toyama Chemical. As well as the antibacterial drug, Toyama Chemical is carrying out research to develop the antifungal drug and the antiviral drug now.
Subjects of research
T-705 (favipiravir), a novel antiviral agent, was discovered by the Research Laboratories of Toyama Chemical Co., Ltd. This compound was selected as a clinical candidate based on its remarkable therapeutic efficacy demonstrated in mice infected with influenza virus in collaboration with Professor Kimiyasu Shiraki of Faculty of Medicine at Toyama University.
T-705 possesses potent and broad spectrum antiviral activity against multiple strains of influenza virus infection in vitro and in vivo. Furthermore, the potent antiviral activity of T-705 against H5N1 influenza virus dreaded as a pandemic-provoking virus has been reported by Utah State University(U.S.) and Tokyo University.
T-705 is clearly-characterized by the novel mechanism of action that is different from the existing anti-influenza viral drugs. By host cellular enzymes, T-705 is converted to the active form, ribofuranosyl triphosphate (T-705RTP), and T-705RTP selectively and directly inhibits the viral replication enzyme, RNA dependent RNA polymerase. In addition, T-705 shows antiviral activity against resistant viruses to existing drugs due to the novelty of mechanism of action.
T-3912 is a new type of topical quinolone antibacterial agent (ozenoxacin), which has potent antimicrobial activity against major pathogens in various topical infections including P.acnes and drug-resistant bacteria, such as MRSA. Toyama Chemical has licensed T-3912 to Maruho Co., Ltd., for Japan, and Grupo Ferrer Internacional (Spain) for the worldwide territory. Currently, Ferrer and Maruho are developing T-3912 as a dermatological drug.
In Japan, Maruho launched T-3912 (brand name: Zebiax® Lotion 2%) for the treatment of superficial skin infections and acne (accompanied by purulent inflammation) in January 2016.
In Europe, Ferrer, and in the US, Medimetriks Pharmaceuticals, a sublicesee of Ferrer, have submitted a new drug application for ozenoxacin cream for the indication of impetigo.
T-2307's new mechanism of action covers a wide range of antifungal activity, and it has exhibited potent activity against Candida and Aspergillus as well as Cryptococcus, for which few drug therapies are available. Toyama Chemical plans to seek indication for both deep-seated and superficial mycosis. T-2307 is also effective against pathogens resistant to other drugs.